Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8910802 | 0.90 | CYP2C19 (0.31) | — | |
| SCHEMBL16566623 | 0.80 | NPSR1 (0.33) | — | |
| SCHEMBL5767891 | 0.76 | ATM (0.34) | — | |
| SCHEMBL21011643 | 0.75 | — | — | |
| SCHEMBL16516185 | 0.74 | — | — | |
| SCHEMBL22832966 | 0.73 | NPSR1 (0.35) | — | |
| SCHEMBL21058295 | 0.73 | NPSR1 (0.39) | — | |
| SCHEMBL16516184 | 0.72 | — | — | |
| SCHEMBL27035522 | 0.72 | GRM1 (0.31) | — | |
| SCHEMBL7724584 | 0.72 | NPSR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| WO-2015024905-A1 | DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-02-26 | — | — | WO | disclosed |
| WO-2010132768-A1 | ANTIBACTERIAL DERIVATIVES OF SISOMICIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | FFAR3 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.